Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 501–600 of 1,000
Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents
Mayhew, C. N., Perkin, L. M., Zhang, X., Sage, J., Jacks, T., & Knudsen, E. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207503 · Cited by 46
“This result could be due to the Oncogene known influence of p53 on sensitivity to 5-FU (Bunz et al., 1999).”
BackgroundCatalano, A., Caprari, P., Soddu, S., Procopio, A. D., & Romano, M. (2004) · The FASEB Journal · doi:10.1096/fj.04-2258fje · Cited by 40
“In most cases, this is the consequence of genetic or epigenetic inactivation of the tumor suppressor protein p53 (13).”
BackgroundRetractedRavizza, R., Molteni, R., Gariboldi, M. B., Marras, E., Perletti, G., & Monti, E. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.021 · Cited by 38
Jaiswal, A. S., Panda, H., Law, B. K., Sharma, J. P., Jani, J. P., Hromas, R., & Narayan, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123808 · Cited by 41
“Bert Vogelstein (Johns Hopkins University) [24, 25].”
Dai, C., Shi, D., & Gu, W. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.476606 · Cited by 43
A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX
Henry, R. E., Andrysík, Z., París, R., Galbraith, M. D., & Espinosa, J. M. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.498 · Cited by 42
“…to p53 activation, we and others have previously shown that only 5FU and UVC lead to rapid apoptosis in HCT116 cells, whereas the topoisomerase inhibitors lead to cell-cycle arrest mostly in G2/M, and to a lesser extent, in G1 (Donner et al, 2007a; Bunz et al, 1998, 1999; Gomes and Espinosa, 2010).”
Ng, P. L., Rajab, N. F., Then, S., Yusof, Y. A. M., Ngah, W. Z. W., Pin, K. Y., & Looi, M. L. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1300303 · Cited by 38
Functions of MDMX in the Modulation of the p53‐Response
Lenos, K., & Jochemsen, A. G. (2011) · BioMed Research International · doi:10.1155/2011/876173 · Cited by 50
“In the model tested, the HCT116 cells, the 5-FU effects are largely dependent on wild-type p53 function, as shown earlier [58].”
BackgroundTassi, E., & Wellstein, A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.10.014 · Cited by 45
“Disruption of p53 by gene targeting in human colon cancer cells results in cell resistance to different chemotherapeutic agents, as opposed to wild type cells (35).”
BackgroundZhang, Y., Shu, L., & Chen, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801711200 · Cited by 40
Self-citationWang, Y. D., Honores, E. E., Wu, B., Johnson, S., Powell, D. W., Miranda, M., McGinnis, J. P., Discafani, C. M., Rabindran, S. K., Cheng, W. H. Y., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.12.046 · Cited by 38
Preferential killing of p53-deficient cancer cells by reversine
Jèmaà, M., Galluzzi, L., Kepp, O., Boilève, A., Lissa, D., Senovilla, L., Harper, F., Pierron, G., Berardinelli, F., Antoccia, A., et al. (2012) · Cell Cycle · doi:10.4161/cc.20621 · Cited by 40
“p53-deficient tumor cells, we took advantage of a couple of isogenic human colon carcinoma HCT 116 cell lines differing from each other by the status of the TP53 locus.(36) Thus, when employed at a concentration of 5 μM, which we refer to as “high-dose,” reversine killed TP53 human colon carcinoma HCT 116 cells more e…”
BackgroundLoevenich, L. P., Tschurtschenthaler, M., Rokavec, M., Silva, M. G., Jesinghaus, M., Kirchner, T., Klauschen, F., Saur, D., Neumann, J. H. L., Hermeking, H., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1247 · Cited by 39
“…we fi rst performed CRISPR/Cas9 targeting of the wild-type p53 genomic locus in MSI HCT116 colorectal cancer cells, which represent a widely used and well-known cell line model for studying p53/p21 axis-dependent cell cycle effects and the determinants of apoptosis in colorectal cancer (47, 48).”
Evidence That Selenium Binding Protein 1 Is a Tumor Suppressor in Prostate Cancer
Ansong, E., Ying, Q., Ekoue, D. N., Deaton, R., Hall, A. R., Kajdacsy‐Balla, A., Yang, W., Gann, P. H., & Diamond, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127295 · Cited by 38
“Previous work has described the involvement of p53 in the cellular response to 5-FU [23,24].”
BackgroundRole of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.
Thant, A. A., Wu, Y., Lee, J., Mishra, D. K., Garcia, H., Koeffler, H. P., & Vadgama, J. V. (2008) · PubMed · Cited by 37
Cassidy, P. B., Moos, P. J., Kelly, R. C., & Fitzpatrick, F. A. (2002) · PubMed · Cited by 41
Yan, L., Shi, J. H., & Zhu, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01163-1 · Cited by 45
Li, X., Yu, J., Brock, M. V., Tao, Q., Herman, J. G., Liang, P., & Guo, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3413 · Cited by 37
“It was reported before that p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-FU in colorectal cancer [25].”
BackgroundChiu, C., Li, C.-H., Ung, M.-W., Fuh, T.-S., Chen, W.-L., & Fang, K. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.049 · Cited by 41
Triple-negative breast cancer: a clinical update
Cleere, D. W. (2010) · Community Oncology · doi:10.1016/s1548-5315(11)70394-1 · Cited by 36
The IGF-1R/AKT pathway determines cell fate in response to p53
Duan, L., & Maki, C. G. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.09.16 · Cited by 39
“This survival function of p53 results, at least in part, from its ability to promote reversible G1 and G2-phase cell cycle arrests (15,22-24).”
BackgroundLu, L., Li, Z. J., Li, L. F., Wu, W. K. K., Shen, J., Zhang, L., Chan, R. L. Y., Yu, L., Liu, Y. W., Ren, S. X., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.282 · Cited by 39
Banerjee, A. K., Saito, K., Meyer, K., Banerjee, S., Ait‐Goughoulte, M., Ray, R. B., & Ray, R. (2009) · Journal of Virology · doi:10.1128/jvi.00872-09 · Cited by 39
“The DNA-damaging drug, 5-FU, functions in a p53-dependent manner (2).”
BackgroundAhrendt, S. A., Brown, H. M., KOMOROWSKI, R. A., Zhu, Y.-R., Wilson, S. D., Erickson, B. A., Ritch, P. S., Pitt, H. A., & Demeure, M. J. (2000) · Surgery · doi:10.1067/msy.2000.108052 · Cited by 36
Induction of Cullin 7 by DNA damage attenuates p53 function
Jung, P., Verdoodt, B., Bailey, A. O., Yates, J. R., Menssen, A., & Hermeking, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609467104 · Cited by 41
Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis
Klampfer, L., Swaby, L.-A., Huang, J., Sasazuki, T., Shirasawa, S., & Augenlicht, L. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208552 · Cited by 39
“Activation of p53 by 5-FU is enhanced in cells harboring mutant Ras It has been shown that 5-FU-induced apoptosis requires functional p53 in vitro (Arango et al., 2003; Bunz et al., 1999), and that patients harboring WT p53 display improved response to 5-FU (Arango et al., 2001).”
BackgroundLiu, C., Rokavec, M., Huang, Z., & Hermeking, H. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06226-9 · Cited by 42
“…USA) with 10% fetal bovine serum (FBS) (Invitrogen) containing 100 units/ml penicillin and 0.1mg/ml streptomycin at 20% O 2 , 5% CO 2 , and 37°C. p53 -de fi cient and p53 -pro fi cient HCT116 and RKO cells were a gift from Bert Vogelstein (Johns Hopkins Medical School, Baltimore, Maryland, USA) [53].”
MethodCyclin-dependent kinases as targets for cancer therapy
Shah, M. A., & Schwartz, G. K. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22007-5 · Cited by 35
Kundu, M., Greer, Y. E., Dine, J. L., & Lipkowitz, S. (2022) · Cells · doi:10.3390/cells11233717 · Cited by 41
Tezuka, M., Watanabe, H., Nakamura, S., Yu, D. S., Winn Aung, U., Sasaki, T., Shibuya, H., & Miura, M. (2001) · PubMed · Cited by 45
Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
Zheng, X., He, K., Zhang, L., & Yu, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1146 · Cited by 38
“The isogenic cell lines, including PUMA-KO (25), p53-KO (26), and p53-binding site knockout (BS-KO; ref.”
BackgroundSuccessful xenografting of cryopreserved primary pancreatic cancers
Sorio, C., Bonora, A., Orlandini, S., Moore, P. S., Capelli, P., Cristofori, P. G., Negro, G. D., Marchiori, P. N., Gaviraghi, G., Falconi, M., et al. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000343 · Cited by 35
“In the meantime, for applications, such as the evaluation of drug response, the knowledge of the inactivation of a particular gene or molecular pathway of a cellular model is becoming increasingly important for both cell lines and animal models of disease [ 4 ].”
MethodDNA damage induces transcriptional activation of p73 by removing C-EBP repression on E2F1
Marabese, M., Vikhanskaya, F., Rainelli, C., Sakai, T., & Broggini, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg869 · Cited by 40
Ohtsuka, T., Liu, X.-F., Koga, Y., Kitajima, Y., Nakafusa, Y., Ha, C., Lee, S. W., & Miyazaki, K. (2005) · Oncogene · doi:10.1038/sj.onc.1209204 · Cited by 38
“…experimental trials have shown the inactivation of p53 to be correlated with resistance to chemotherapy in colorectal cancers (Lowe et al., 1994; Bunz et al., 1999). p53 is a transcriptional factor, which induces its target genes, such as p21, Bax, Noxa, and Puma, to regulate either cell cycle…”
BackgroundMethodEscalona, E., Muñoz, M., Pincheira, R., Elorza, Á. A., & Castro, A. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01123 · Cited by 37
“Cancer cells lines HCT116 p53 null, kindly provided by Dr. B. Vogelstein (Johns Hopkins Medicine, USA) (21), and HeLa (ATCC R© CCL-2TM, Manassas, VA) were cultured in Dulbecco’s modified Eagles’s medium (DMEM) containing 4.5 g/l glucose, 2mM L-glutamine, and 1mM sodium pyruvate (Corning, New York, USA).”
MethodInfluentialLi, R., Zatloukalová, P., Müller, P., Gil-Mir, M., Kote, S., Wilkinson, S., Kemp, A. J., Hernychová, L., Wang, Y., Ball, K. L., et al. (2020) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-020-00233-w · Cited by 35
Burger, K., & Eick, D. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0153 · Cited by 40
Hypoxia Inducible Factor Pathways as Targets for Functional Foods
Losso, J. N., & Bawadi, H. A. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0479719 · Cited by 43
Khan, S. A., Zeng, Z., Shia, J., & Paty, P. B. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0166-2 · Cited by 34
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
Kong, L. R., Ong, R., Tan, T. Z., Salleh, N. A. B. M., Thangavelu, M. T., Chan, J. V., Koh, L. Y. J., Periyasamy, G., Lau, J. A., Le, T. B. U., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15608-y · Cited by 38
Chen, X.-X. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i5.841 · Cited by 33
Essential role for focal adhesion kinase in regulating stress hematopoiesis
Vemula, S., Ramdas, B., Hanneman, P., Martin, J., Beggs, H. E., & Kapur, R. (2010) · Blood · doi:10.1182/blood-2010-01-262790 · Cited by 35
Regulation of apoptosis by the papillomavirus E6 oncogene
Li, T., Zhao, L.-N., Liu, Z.-G., Han, Y., & Fan, D.-M. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i7.931 · Cited by 38
Naydenov, N. G., Harris, G., Brown, B., Schaefer, K. L., Das, S. K., Fisher, P. B., & Ivanov, A. I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.278358 · Cited by 36
BAX/BAK–Independent Mitoptosis during Cell Death Induced by Proteasome Inhibition?
Lomonosova, E. E., Ryerse, J. S., & Chinnadurai, G. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0183 · Cited by 34
“Thus, the p53-deficient cells were sensitive to the effects of DNA-damaging agents, had the same apoptotic response to sulindac as wt cells, but became resistant to the toxicity of the antimetabolite 5-fluorouracil (17, 21).”
BackgroundID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through Inhibition of p21
Geng, H., Rademacher, B. L. S., Pittsenbarger, J., Huang, C.-Y., Harvey, C. T., Lafortune, M. C., Myrthue, A., Garzotto, M. G., Nelson, P. S., Beer, T. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3186 · Cited by 35
Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status
Williams, J. R., Zhang, Y., Russell, J., Koch, C. J., & Little, J. B. (2007) · Acta Oncologica · doi:10.1080/02841860601080407 · Cited by 35
“2, that has been abrogated for the TP53 gene [17].”
BackgroundSelf-citationStimulus-Specific Transcriptional Regulation Within the p53 Network
Donner, A. J., Hoover, J. M., Szostek, S. A., & Espinosa, J. M. (2007) · Cell Cycle · doi:10.4161/cc.6.21.4893 · Cited by 40
SMG7 is a critical regulator of p53 stability and function in DNA damage stress response
Luo, H., Cowen, L. E., Yu, G., Jiang, W. G., & Tang, Y. (2016) · Cell Discovery · doi:10.1038/celldisc.2015.42 · Cited by 41
Ding, Z., Parchment, R. E., LoRusso, P. M., Zhou, J. Y., Li, J., Lawrence, T. S., Sun, Y., & Wu, G. S. (2001) · PubMed · Cited by 33
Zhang, Z., Wang, Y., Lantry, L. E., Kastens, E., Liu, G., Hamilton, A. D., Sebti, S. M., Lubet, R. A., & You, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206630 · Cited by 33
“This observation is consistent with the finding that p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21 (Bunz et al., 1999).”
ResultElsaleh, H., Shannon, B. A., & Iacopetta, B. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.23646 · Cited by 33
BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53‐null colon cancers
Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M. G., Pisano, F., Missaglia, C., Giovannoni, R., Romano, G., McLean, C. M., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5347 · Cited by 32
“Therefore, we sought to determine the effect of p65BTK inhibition on the response of drug-resistant colon cancer cells to 5-FU, using the well characterised model of drug-resistance represented by HCT116p53KO cells treated with 200 μM 5-FU [26].”
MethodTranslational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine
Palomar-Siles, M., Heldin, A., Zhang, M., Strandgren, C., Yurevych, V., van Dinter, J. T., Engels, S. A. G., Hofman, D. A., Öhlin, S., Meineke, B., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05431-2 · Cited by 32
“This is of particular interest given that p53 is crucial for the apoptotic response of tumor cells to 5-FU [34].”
BackgroundAKT regulates NPM dependent ARF localization and p53mut stability in tumors
Hamilton, G., Abraham, A., Morton, J. P., Sampson, O. L., Pefani, D., Khoronenkova, S. V., Grawenda, A. M., Papaspyropoulos, A., Jamieson, N. B., McKay, C. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2178 · Cited by 39
“TP53 is an important mediator of cell death responses to commonly used therapeutic agents that elicit DNA damage [11-13].”
BackgroundIshizaki, H., Song, G.-Y., Srivastava, T., Carroll, K. D., Shahabi, V., Manuel, E. R., Diamond, D. J., & Ellenhorn, J. D. I. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e032c6 · Cited by 32
“p53 overexpression is an independent predictor of more aggressive malignancy and failure to respond to standard therapeutic regimens, and ultimately of cancer-related mortality.(2,3) Mutations of p53 are associated with elevated nuclear and cytoplasmic concentration of the p53 protein.”
BackgroundLorenzi, F., Babaei‐Jadidi, R., Sheard, J., Spencer‐Dene, B., & Nateri, A. S. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.24 · Cited by 42
Lee, E. J., Gerhold, M., Palmer, M. W., & Christen, R. D. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600779 · Cited by 35
“…Korea To determine the role of p53 protein on the cellular effects of amifostine, we used molecularly engineered HCT116 colon cancer cells in which the p53 gene was inactivated by targeted homologous recombination or p53 protein was degraded by high-level expression of papillomavirus E6 protein.”
MethodFang, Y., Linardic, C. M., Richardson, D. A., Cai, W., Behforouz, M., & Abraham, R. T. (2003) · PubMed · Cited by 41
Derangement of growth and differentiation control in oncogenesis
Corn, P. G., & El‐Deiry, W. S. (2002) · BioEssays · doi:10.1002/bies.10036 · Cited by 46
Cyclic Pifithrin-α Sensitizes Wild Type p53 Tumor Cells to Antimicrotubule Agent–Induced Apoptosis
Zuco, V., & Zunino, F. (2008) · Neoplasia · doi:10.1593/neo.08262 · Cited by 31
Kashofer, K., & Regauer, S. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.018 · Cited by 33
Yang, Z., Lee, M. M. M., & Chan, M. K. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120759 · Cited by 32
Curcuma as an adjuvant in colorectal cancer treatment
Villegas, C., Perez, R., Sterner, O., González‐Chavarría, I., & Paz, C. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120043 · Cited by 35
Horiguchi, H., Endo, M., Miyamoto, Y., Sakamoto, Y., Odagiri, H., Masuda, T., Kadomatsu, T., Tanoue, H., Motokawa, I., Terada, K., et al. (2014) · Cancer Science · doi:10.1111/cas.12554 · Cited by 31
Striefler, J. K., Sinn, M., Pelzer, U., Jühling, A., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Dörken, B., Oettle, H., et al. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.001 · Cited by 31
Derouet-Hümbert, E., Roemer, K., & Bureik, M. (2005) · Biological Chemistry · doi:10.1515/bc.2005.054 · Cited by 34
“…(human melanoma) (Meissauer et al., 1991); it reduced the viability of HCT116 p53-/- cells (HCT116 with a targeted disruption of both p53 alleles; Bunz et al., 1999), U373-MG cells (human glioblastoma), C6 cells (rat malignant glioma), and T47D cells (human breast cancer), while the survival…”
BackgroundGokare, P. R., Finnberg, N. K., Abbosh, P. H., Dai, J., Murphy, M. E., & El‐Deiry, W. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09859-x · Cited by 33
“…the p53 tumor suppressor protein controls 5-FU catabolism by repressing the expression of the key rate limiting enzyme in pyrimidine degradation DPYD. p53 has a well-documented function in the cell death response following 5-FU treatment in pre-clinical experiments in vitro and in vivo 19, 43 .”
Therachiyil, L., Haroon, J., Sahir, F., Siveen, K. S., Shahab Uddin, M. S., Kuliński, M., Buddenkotte, J., Steinhoff, M. S., & Krishnankutty, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01744 · Cited by 31
Down-regulation of p21 contributes to apoptosis induced by HPV E6 in human mammary epithelial cells
Fan, X., Liu, Y., & Chen, J. J. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6062-y · Cited by 34
Activation of p53 protein by telomeric (TTAGGG)n repeats
Milyavsky, M., Mimran, A., Senderovich, S., Zurer, I., Erez, N., Shats, I., Goldfinger, N., Cohen, I., & Rotter, V. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.24.5207 · Cited by 33
“For this purpose, we used the HCT116 colon cancer-derived cell line containing wild type p53 as well as functional DNA damage checkpoints (61,62).”
MethodKawasumi, M., Bradner, J. E., Tolliday, N. J., Thibodeau, R. M., Sloan, H., Brummond, K. M., & Nghiem, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2650 · Cited by 32
“p53-deficient cells are resistant to DNA-damaging agents (37), and there is, thus, a need to sensitize p53-deficient cells for effective cancer therapy.”
BackgroundEisold, S. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i24.3583 · Cited by 30
“Expression of wt- p53 has been shown to be required for 5-FU- induced apoptosis and to greatly potentiate 5-FUcytotoxicity[3, 4 ].”
BackgroundResultKim, Y.-S., Kim, S., & Park, S. J. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.03.015 · Cited by 30
Mostofa, A., Punganuru, S. R., Madala, H. R., & Srivenugopal, K. S. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.010 · Cited by 34
Jin, H. R., Du, C. H., Wang, C., Yuan, C., & Du, W. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1548-7 · Cited by 31
Darragh, J., Hunter, M. J., Pöhler, E., Nelson, L., Dillon, J. F., Nenutil, R., Vojtesek, B., Ross, P. E., Kernohan, N., & Hupp, T. R. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05206.x · Cited by 32
Kobayashi, H., Tan, E. M., & Fleming, S. E. (2003) · Nutrition and Cancer · doi:10.1207/s15327914nc4602_14 · Cited by 30
“Also, inactivation of p53 causes resistance to various cancer therapies including use of an angiogenesis inhibitor (27) and 5-fluorouracil (28).”
BackgroundTorsello, A., Garufi, C., Cosimelli, M., Diodoro, M. G., Zeuli, M., Vanni, B., Campanella, C., D’Angelo, C., Sperduti, I., Donnorso, R. P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.002 · Cited by 30
Tian, H., Faje, A. T., Lee, S. L., & Jorgensen, T. J. (2002) · Neoplasia · doi:10.1038/sj.neo.7900219 · Cited by 32
“The HCT116 human colon cancer cell line was chosen for this study because wild- type cells have intact p53, p21, and 14-3-3 genes and apparently normal p53-dependent checkpoint responses [18,19], whereas its p53-deficient isogenetic counterpart has been shown to fail to sustain both G1 and G2 arrest [15,30].”
BackgroundMethodThe Synergistic Effect of 5-Aza-2′-Deoxycytidine and 5-Fluorouracil on Drug-Resistant Tumors
Morita, S., Iida, S., Kato, K., Takagi, Y., Uetake, H., & Sugihara, K. (2006) · Oncology · doi:10.1159/000107110 · Cited by 29
Oshima, K., Naoi, Y., Kishi, K., Nakamura, Y., Iwamoto, T., Shimazu, K., Nakayama, T., Kim, S. J., Baba, Y., Tamaki, Y., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.027 · Cited by 29
“, immunohistochemistry, sequencing, or other methods [8,9,16–18].”
Lin, S., Yu, L., Song, X., Bi, J., Jiang, L., Wang, Y., He, M., Xiao, Q., Sun, M., Olopade, O. I., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1871-z · Cited by 32
Tsymbal, S. A., Moiseeva, A. A., Agadzhanian, N., Efimova, S. S., Markova, A. A., Guk, D. A., Krasnovskaya, O. O., Alpatova, V. M., Зайцев, А. В., Shibaeva, A. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011065 · Cited by 29
“Posypanova, National Research Center ‘The Kurchatov Institute’, Moscow, Russia) [24,25,35].”
BackgroundWittmann, C., Bacher, F., Enyedy, É. A., Dömötör, O., Spengler, G., Madejski, C., Reynisson, J., & Arion, V. B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01740 · Cited by 29
Berge, G., & Mælandsmo, G. M. (2010) · Amino Acids · doi:10.1007/s00726-010-0497-3 · Cited by 32
“The best example being the human colon cancer cell line HCT116 which is verified wt TP53, and still expresses high levels S100A4, while the isogenic TP53 knock-out variant (TP53-/-) ( Bunz et al. 1999 ) exhibit very low levels (Daoud et al. 2003; Mann and Hainaut 2005; Berge et al. 2010).”
BackgroundInactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin
Xu, G. W., Mymryk, J. S., & Cairncross, J. G. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-6601-3 · Cited by 29
IGF-1 activates p21 to inhibit UV-induced cell death
Murray, S. A., Zheng, H., Gu, L., & Xiao, Z. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206327 · Cited by 32
“Similarly, targeted deletion of p21 in human colon cancer cell lines results in enhanced susceptibility to apoptosis induced by chemotherapeutic agents (Bunz et al., 1999).”
BackgroundBronder, J. L., & Moran, R. G. (2002) · PubMed · Cited by 29
Kennedy, A. S., Harrison, G. H., Mansfield, C. M., Zhou, X. J., Xu, J., & Balcer‐Kubiczek, E. K. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000820)90:4<199::aid-ijc3>3.0.co;2-c · Cited by 29
TP53 and Let-7a micro-RNA Regulate K-Ras Activity in HCT116 Colorectal Cancer Cells
Luu, C., Heinrich, E. L., Duldulao, M. P., Arrington, A. K., Fakih, M., García‐Aguilar, J., & Kim, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070604 · Cited by 29
“These cells were derived from a parental cell line harboring the gain of function KRAS mutation located on codon 13 [28,29].”
BackgroundLi, X., Li, Y., Hu, J., Wang, B., Zhao, L., Ji, K., Guo, B., Yin, D., Du, Y., Kopecko, D. J., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.034 · Cited by 31
“In certain other cancers, however, active p53 may either enhance or inhibit the response to therapeutic agents [17,18].”
Mohr, A., Deedigan, L., Jencz, S., Mehrabadi, Y., Houlden, L., Albarenque, S. M., & Zwacka, R. M. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.164 · Cited by 33
“Next, we analysed whether 5FU-induced caspase-8 activation was p53 dependent.(21) We compared p53-proficient HCT116 and HCTp53− /− cells for caspase-8 activity following 5FU treatment.”
BackgroundGmeiner, W. H., Miller, L. D., Chou, J. W., Dominijanni, A. J., Mutkus, L. A., Marini, F. C., Ruiz, J., Dotson, T. L., Thomas, K. W., Parks, G. E., et al. (2020) · Cancers · doi:10.3390/cancers12040788 · Cited by 32
“Further, F10 was equipotent to cancer cells regardless of p53 status [20], which is important for treating p53-null SCLC [21,22].”
BackgroundPARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models
Wilson, T. C., Pirovano, G., Xiao, G., Samuels, Z. V., Roberts, S. S., Viray, T. D., Guru, N., ZANZONICO, P. B., Gollub, M. J., Pillarsetty, N., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00323 · Cited by 31
Improving the selectivity of cancer treatments by interfering with cell response pathways
Damia, G. L. M., & Broggini, M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.020 · Cited by 29
“Different isogenic cellular systems have been generated with the aim of determining the role of p53 in the cell s response to treatment [58–64] and these systems can be used to screen new molecules with enhanced activity in p53-mutated cancer cells.”
MethodGodai, T., Suda, T., Sugano, N., Tsuchida, K., Shiozawa, M., Sekiguchi, H., Sekiyama, A., Yoshihara, M., Matsukuma, S., Sakuma, Y., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-420 · Cited by 34
“Although Bunz et al. demonstrated in vitro that the apoptosis-inducing effect of 5-FU was almost abrogated when they deleted TP53 in the wildtype TP53 carrying human colon cancer cell, HCT116 [39], this situation is quite different from the actual clinical setting in which p53 function was knocked out not by homozygou…”
BackgroundInfluentialNimbalkar, D., Henry, M. K., & Quelle, F. W. (2003) · PubMed · Cited by 28
López-Royuela, N., Galán‐Malo, P., Galán‐Malo, P., Yuste, V. J., Anel, A., Susín, S. A., Naval, J., & Marzo, I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.02.010 · Cited by 28
Notch1 phenotype and clinical stage progression in non-small cell lung cancer
Nguyen, D., Rubinstein, L., Takebe, N., Miele, L., Tomaszewski, J. E., Ivy, P. S., Doroshow, J. H., & Yang, S. X. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0104-2 · Cited by 29
“buffer and proteins in the lysates were separated by electrophoresis [31].”
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.